Autolus Therapeutics plc ADR (NASDAQ: AUTL) kicked off on Monday, down -4.57% from the previous trading day, before settling in for the closing price of $3.50. Over the past 52 weeks, AUTL has traded in a range of $2.89-$7.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 190.29% over the last five years. While this was happening, its average annual earnings per share was recorded 31.59%. With a float of $236.60 million, this company’s outstanding shares have now reached $266.05 million.
The firm has a total of 463 workers. Let’s measure their productivity. In terms of profitability, gross margin is 52.27%, operating margin of -1518.81%, and the pretax margin is -1845.81%.
Autolus Therapeutics plc ADR (AUTL) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Autolus Therapeutics plc ADR is 11.07%, while institutional ownership is 55.63%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 31.59% per share during the next fiscal year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Take a look at Autolus Therapeutics plc ADR’s (AUTL) current performance indicators. Last quarter, stock had a quick ratio of 18.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 84.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Analysing the last 5-days average volume posted by the [Autolus Therapeutics plc ADR, AUTL], we can find that recorded value of 2.92 million was better than the volume posted last year of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 5.69%. Additionally, its Average True Range was 0.27.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 11.47%, which indicates a significant increase from 1.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.98% in the past 14 days, which was higher than the 67.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.01, while its 200-day Moving Average is $4.62. Now, the first resistance to watch is $3.49. This is followed by the second major resistance level at $3.65. The third major resistance level sits at $3.74. If the price goes on to break the first support level at $3.25, it is likely to go to the next support level at $3.16. Should the price break the second support level, the third support level stands at $3.01.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
The company with the Market Capitalisation of 888.61 million has total of 266,094K Shares Outstanding. Its annual sales at the moment are 1,700 K in contrast with the sum of -208,380 K annual income. Company’s last quarter sales were recorded 10,090 K and last quarter income was -52,690 K.
